In B-cell lymphoma, Galli et al. found that patients with complete or partial responses at three and six months after CAR-T cell infusion had a lower CD4+/CD8+ ratio in the infused CAR-T products compared with non-responders. Here, CD8A is linked to B-cell non-Hodgkin lymphoma.